Capricor Therapeutics, Inc.
NASDAQ:CAPRBiotechnology
-$0.14 today
- Market cap
- $465.03M
- Beta
- 0.37
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$2.00
Volume 8.33M
Average 1.08M
CAPR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Capricor Therapeutics, Inc.NASDAQ: CAPR
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$33.41M, compared with -$23.99M a year earlier. Trailing-twelve-month EBITDA was $893.33M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of -$79.28M (+20.8%) for the fiscal year ending Dec 2026, a step up from the -156.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$33.41M-103.4% QoQ
- Last fiscal yearDec 2025
- -$100.11M-156.4% YoY
- LTMMar 2026
- $893.33M+1767.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -39.3% | +1129.1% | +1168.4 pp |
| 1 year | -156.4% | +20.8% | +177.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (100.11M) USD
- Year-over-year change
- -156.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (100.11M) | -156.4% |
| FY2024 | 2024-12-31 | (39.04M) | -84.0% |
| FY2023 | 2023-12-31 | (21.22M) | +25.5% |
| FY2022 | 2022-12-31 | (28.49M) | -44.0% |
| FY2021 | 2021-12-31 | (19.78M) | — |
EBITDA vs competitors
How CAPR compares with its peers on the latest reported figures
- CAPR's LTM Mar 2026 EBITDA of $893.33M is the highest of the 10 companies compared; the peer median is -$174.59M.
- Its year-over-year change of +1767.7% is the highest of 10, against a peer median of -38.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $893.33M | +1767.7% | — | — | |
| LTM Jun 2026 | $173.52M | -79.4% | — | 17.2% | |
| LTM Mar 2026 | $124.95M | +217.3% | — | 5.7% | |
| LTM Mar 2026 | -$75.99M | +22.0% | — | — | |
| LTM Mar 2026 | -$164.87M | -697.5% | — | 2873.3% | |
| LTM Mar 2026 | -$174.59M | -68.4% | — | 243.2% | |
| LTM Mar 2026 | -$190.1M | -38.9% | — | — | |
| LTM Sep 2026 | -$200.94M | -29.7% | — | — | |
| LTM Sep 2026 | -$473.54M | -208.3% | — | 49.3% | |
| LTM Jun 2026 | -$495.35M | -20.6% | — | — | |
| Peer median (excluding CAPR) | -$174.59M | -38.9% | — | 49.3% | |
Competitors are the stored peer set for CAPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 244.9K | 2.55M | 25.18M | 22.27M | 0 |
| Cost of Revenue | 0 | 21.82M | 36.45M | 49.97M | 0 |
| Gross Profit | 244.9K | (19.27M) | (11.27M) | (27.7M) | 0 |
| Gross Margin | 100.0% | -755.1% | -44.8% | -124.4% | — |
| Research & Development | 13.57M | 21.82M | 36.45M | 49.97M | 84.45M |
| Selling, General & Admin | 7.61M | 10.43M | 12.81M | 14.87M | 22.75M |
| Operating Expenses | 21.18M | 10.43M | 12.81M | 14.87M | 108.14M |
| Depreciation & Amortization | 245.7K | 533.13K | 1.07M | 1.43M | 1.89M |
| EBITDA | (19.78M) | (28.49M) | (21.22M) | (39.04M) | (100.11M) |
| EBITDA Margin | -8075.5% | -1116.5% | -84.3% | -175.3% | — |
| Operating Income | (20.94M) | (29.7M) | (24.08M) | (42.56M) | (108.14M) |
| Operating Margin | -8549.9% | -1163.9% | -95.6% | -191.1% | — |
| Interest Income | 0 | 521.53K | 1.73M | 2.2M | 6.26M |
| Interest Expense | 0 | 0 | 0 | 0 | 3.05M |
| Other Income / Expenses | 915.92K | 677.85K | 1.79M | 2.1M | 3.1M |
| Income Before Tax | (20.02M) | (29.02M) | (22.29M) | (40.47M) | (105.04M) |
| Pre-Tax Margin | -8175.9% | -1137.4% | -88.5% | -181.7% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (20.02M) | (29.02M) | (22.29M) | (40.47M) | (105.04M) |
| Net Margin | -8175.9% | -1137.4% | -88.5% | -181.7% | — |
| EPS (Basic) | (0.87) | (1.18) | (0.83) | (1.15) | (2.26) |
| EPS (Diluted) | (0.87) | (1.18) | (0.83) | (1.15) | (2.26) |
| Weighted Avg Shares | 23.09M | 24.55M | 26.78M | 35.22M | 46.48M |
| Weighted Avg Shares (Diluted) | 23.09M | 24.55M | 26.78M | 35.22M | 46.48M |
Capricor Therapeutics, Inc.
NASDAQ:CAPR
Intrinsic Alpha fair value
Locked
Current Price
$8.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.